DiaMedica Therapeutics
DiaMedica Therapeutics, a clinical-stage biopharmaceutical company, develops treatments for strokes and kidney disease.
Founded
2000DiaMedica Therapeutics, a clinical-stage biopharmaceutical company, develops treatments for strokes and kidney disease.
Founded in Minneapolis, Minnesota, DiaMedica Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for acute ischemic strokes and diabetic kidney disease. The company's core mission is to improve the lives of patients suffering from these severe medical conditions through groundbreaking pharmaceutical solutions. DiaMedica's primary product in development is DM199, a recombinant form of the human protein KLK1, which is currently undergoing pivotal Phase 2 trials.
DiaMedica Therapeutics has garnered attention from notable investors and industry leaders due to its promising research and development efforts. The company has achieved significant milestones, including the successful dosing of the first patient in its ReMEDy2 trial for DM199. This progress underscores DiaMedica's potential impact on stroke and kidney disease treatment, positioning it as a key player in the biopharmaceutical landscape.
Companies similar to DiaMedica Therapeutics include Neumedics, MDI Therapeutics, Dianomi Therapeutics and Medinox.
DiaMedica Therapeutics was founded in 2000.
DiaMedica Therapeutics' headquarters is located in Minneapolis, MN, US.
DiaMedica Therapeutics' most recent funding round was for $37.5M (USD) in June 2023.
As of Jun 21, 2023, DiaMedica Therapeutics has disclosed funding of $125.4M (USD). Undisclosed round amounts are excluded.
DiaMedica Therapeutics has 14 employees as of Feb 6, 2024.
Medinox
medinox.com
